针对多发性骨髓瘤的双特异性抗体:过去,现在和未来
Toshiki Ochi1,2, Tatsuya Konishi3, Katsuto Takenaka3
1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan. ochi.toshiki.eg@ehime-u.ac.jp.
International journal of hematology
|April 13, 2024
概括
双特异性抗体为耐火性多发性骨髓瘤提供了有前途的免疫疗法,在临床试验中取得了成功. 仔细管理免疫效应对于最佳治疗结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 多发性骨髓瘤仍然是一个无法治愈的恶性瘤,尽管治疗方面取得了进展.
- T细胞重定向免疫疗法,包括嵌合抗原受体 (CAR) -T细胞和双特异性抗体,对耐火性髓瘤有希望.
- 针对性/非针对性免疫效应需要仔细考虑和管理.
研究的目的:
- 审查最近对治疗耐火性多发性髓瘤的双特异性抗体的进展.
- 讨论双特异抗体的发展,作用机制和治疗作用.
- 探索双特异性抗体治疗的最佳时间,与其他治疗方法 (如CAR-T细胞) 相比.
主要方法:
- 对多发性骨髓瘤中双特异性抗体的最新临床试验和科学文献的综述.
- 对作用机制和与免疫相关的不良事件的分析.
- 对双特异性抗体与其他免疫疗法 (如CAR-T细胞) 的比较.
主要成果:
- 双特异性抗体已经在三重类耐药患者中证明了成功的抗髓瘤反应.
- 临床试验显示有效性,他们的"现成"性质提供了治疗时间优势.
- 了解和管理免疫效应对于成功应用至关重要.
结论:
- 双特异性抗体代表了耐火性多发性髓瘤治疗的重大进展.
- 鼓励进一步开发和结合策略以提高疗效.
- 优化治疗时间和管理免疫反应是未来应用的关键.
相关概念视频
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


